3 Results for "

Lewy Body Disease (LBD)

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "Lewy Body Disease (LBD)" in MCE Product Catalog:

Cat. No.: HY-178920
CAS No.: 676458-63-2
Target:  

α-synuclein

Research Areas:  

Neurological Disease

α-Synuclein-IN-17 (Compound 10) is an α-Synuclein inhibitor, with an IC50 value of 9 μM. α-Synuclein-IN-17 exhibits potent inhibitory activity against both in-vitro assembled asyn fibrils and LBD brain tissue-amplified asyn fibrils. α-Synuclein-IN-17 can be used for the study of Parkinson's disease (PD) and Lewy Body Disease (LBD) .
loading...
    loading...
Cat. No.: HY-175308
CAS No.: 414880-30-1
Target:  

α-synuclein

Research Areas:  

Neurological Disease

α-Synuclein inhibitor 15 (Compound 1) is an inhibitor targeting the fibrillation growth of α-synuclein (IC50=18 μM). α-Synuclein inhibitor 15 is promising for research of neurodegenerative diseases, such as Parkinson's disease (PD) and Lewy body dementia (LBD) .
loading...
    loading...
Cat. No.: HY-182893
CAS No.: 1919889-97-6
SK-129 is a blood-brain barrier-permeable inhibitor of α-synuclein (αS) oligomers with a Kd of 221 nM. SK-129 preferentially binds to neurotoxic αS oligomers over physiological αS monomers, inhibits αS aggregation, blocks the interaction and co-aggregation of αS with tau protein, and prevents the maturation of αS-tau condensates into amyloid aggregates. SK-129 reduces ROS production, rescues dopaminergic neuron degeneration, improves motor function, restores endogenous dopamine synthesis, increases the number of Tyrosine Hydroxylase-positive neurons, prevents brain histopathological changes, alleviates neuroinflammation, and improves survival rates in relevant models. SK-129 can be used in research related to Parkinson's disease (PD) and Lewy body dementia (LBD) .
loading...
    loading...